// App-Quantinova.ai

2740 : Mechanistic basis of Palbociclib combinatorial activity in ER+ breast cancer and non-breast indications

Researchers

Presenter

  • Stephen Dann

Principal Investigators

  • Jing Yuan

  • John Chionis

  • Chaoting Liu

  • Tao Xie

  • Nathan V. Lee

  • Enhong Chen

  • Ping Wei

  • Paul A. Rejto

  • David J. Shields

  • Todd Van Arsdale

Medical Centers

  • Pfizer Oncology, La Jolla, CA

  • Pfizer Inc, Pearl River, CA.

Locations

  • United States

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Retinoblastoma

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Cyclin-dependent kinase 4

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Palbociclib

  • Letrozole

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved